CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company
Ernexa Therapeutics Inc.
Sign in to watch- Ticker
- ERNA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 311103425
- Phone
- (617) 798-6700
- Business address
- 1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
- Former names
- Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC
Securities
- ERNA Common Stock Nasdaq
- ERNAW Warrants Nasdaq
- 8-K Event Material agreement
- 4 Open-market sale 10% owner sold 2,310 shares at $8.50 ($19,635)
- UPLOAD Other SEC-generated Letter
- 4 Open-market sale 10% owner sold 5,752 shares at an average $8.84 ($50,838)
- S-3 Offering Registration Statement
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Other events
- 4 Grant or award CFO and EVP acquired 1,000 shares (grant or award)
- 4 Open-market buy Director bought 5,620 shares at an average $7.24 ($40,679)
- SC 13D/A Stake Beneficial Ownership Report
- 3 Insider Initial Statement of Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Grant or award SVP Marketing acquired 7,531 shares (grant or award)
- 4 Grant or award CFO and EVP acquired 29,500 shares (grant or award)
- 4 Grant or award CEO acquired 30,000 shares (grant or award)
- 8-K Event Other events
- 424B5 Offering Prospectus
- 8-K Event Material agreement · Results of operations · Other events
- 8-K Event Other events
Page 37 of 77 · 1,525 filings